Applications of (1S,2S)-(+)-2-Amino-1-[4-(Methylthio)Phenyl]-1,3-Propanediol in Industrial Manufacturing

This chiral amino alcohol serves as a critical raw material in several specialized manufacturing sectors. Its unique stereochemistry and functional groups enable distinctive performance and regulatory compliance for controlled industrial applications.

1. Chiral Intermediate for Antihypertensive Pharmaceutical APIs

This compound functions as a dedicated chiral building block for synthesizing selective beta-blocker APIs, especially those containing methylthio substitution on the aromatic ring. Downstream manufacturers employ it in multi-step stereoselective synthesis, targeting high purity requirements for final pharmaceutical actives. The diol and amino functionalities support both protecting group strategies and direct coupling reactions. Specific chiral retention is critical for activity and regulatory approval.

Industry compliance standards

• ICH Q7: Good Manufacturing Practice for Active Pharmaceutical Ingredients
• USP–NF and EP monographs for chiral drug substances
• 21 CFR Part 210/211 (cGMP for finished pharmaceuticals)
• FDA guidances regarding stereoisomeric API synthesis

Typical usage ratio

• Ranges from 0.85 to 1.1 molar equivalents relative to the desired API core, depending on downstream step yields and protection group strategies

Downstream process integration

• Entry point after core aromatic alkylation, typically as a nucleophilic coupling agent or diol precursor prior to cyclization and further amination
• Utilized during enantioselective intermediate formation for final deprotection and crystallization

Final product types

• Chiral antihypertensive APIs: e.g. nebivolol, newer beta-adrenergic blockers with specific stereochemistry
• API intermediate batches for regulated export

2. Precursor in CNS Active Compound Synthesis (Nootropic & Alzheimer’s API Manufacturing)

Manufacturing plants use this precursor for assembling central nervous system (CNS) drug intermediates where both chiral configuration and heteroaromatic substitution play roles in receptor selectivity and metabolic profile. The methylthio group offers pathway flexibility for downstream sulfoxidation or further functionalization. Manufacturers ensure precise configuration, working under validated analytical controls to guarantee suitability for final CNS therapy incorporation.

Industry compliance standards

• EU GMP Vol. 4 (Annex 1 & 2 for obligate intermediates)
• Ph. Eur., JP, and USP standards for CNS actives
• REACH Registration (if supplied intra-EU for specialty pharma)

Typical usage ratio

• Between 1.0 and 1.2 equivalents per API intermediate batch, validated by HPLC chiral purity to ±0.5%

Downstream process integration

• Deployed in the stepwise assembly of piperidine and pyrrolidine CNS-active cores, especially requiring sulfur derivatization post-condensation
• Feeds multi-step synthesis, usually post-oxidation and prior to final salt formation and API isolation

Final product types

• Pilot and production scale CNS APIs for Alzheimer’s and cognitive enhancer drugs
• Chiral intermediates for original research molecule supply

3. Component in Chiral Ligand Production for Asymmetric Hydrogenation Catalysts

Chemical manufacturers use this material to produce specialized chiral ligands, particularly for ruthenium- and rhodium-based asymmetric hydrogenation systems. The stereochemical arrangement of the amino and diol groups imparts catalytic enantioselectivity. End users demand precisely defined batch purity and configuration, tracked by validated enantiomeric ratio analysis. The methylthio aromatic substituent enables tailored electronic effects for downstream ligand optimization.

Industry compliance standards

• ISO 9001:2015 Quality Management for organometallics production
• Sigma-Aldrich and Strem Chemicals technical supply chain protocols
• Environmental and safety standards: OSHA Process Safety Management (when handling organometallic catalysts)

Typical usage ratio

• Dosage typically at 1 equivalent per ligand molecular design; scale adjusted per specific catalyst batch but monitored for ligand-to-metal ratio with ±2% tolerance

Downstream process integration

• Introduced during ligand backbone assembly; functionalized prior to complexation with precious metals
• Post-condensation purification ensures minimal diastereomeric and enantiomeric impurity in ligand feedstock

Final product types

• Chiral diphosphine or diamine-based ligands for industrial hydrogenation
• Precious metal-ligand catalysts distributed to API and fine chemical plants

4. Stereoselective Building Block for Agrochemical Active Ingredients

Agrochemical manufacturers select this material as a precursor for advanced fungicides and insecticides that require precise chiral environment and selective aromatic sulfur functionality. The compound’s stereochemistry influences bioavailability and non-target organism safety. Typical process integration includes coupling with heterocyclic moieties and subsequent methylthio oxidation, with production batches controlled for residual chiral precursor and related substances.

Industry compliance standards

• FAO/WHO: Specifications and evaluations for agricultural pesticide chemicals
• OECD Principles of Good Laboratory Practice for field trials
• REACH for agrochemical intermediates (where applicable)

Typical usage ratio

• Ranges from 0.9–1.05 equivalents per target molecule, adjusted to synthetic pathway yield and regulatory impurity limits

Downstream process integration

• Incorporation during heterocycle coupling and post-functionalization in the pesticide core assembly
• Crude batch optimization ensures minimal racemization and high recovery of the active stereoisomer

Final product types

• Chiral triazole, azole, and phenylthio-substituted agrochemicals
• Advanced insecticidal and fungicidal actives exported for mixture formulation